The opioid overdose epidemic, which has been markedly exacerbated by fentanyl,
highlights the urgency for psychiatrists to be well versed on the proper screening and …

Alcohol abuse is a leading risk factor for the public health burden worldwide. Approved
pharmacotherapies have demonstrated limited effectiveness over the last few decades in …

The potential of psychedelics to persistently treat substance use disorders is known since
the 1960s. However, the biological mechanisms responsible for their therapeutic effects …

Background: The classical psychedelics psilocybin, peyote, ayahuasca/N, N-
dimethyltryptamine, and lysergic acid diethylamide can temporarily produce altered states of …

This systematic review analyzes the current literature on the potential therapeutic use of
classic psychedelics (ie, psilocybin, lysergic acid diethylamide [LSD], N, N …

Introduction A new era of treatment for adults with treatment-resistant depression (TRD),
which involves psychedelic substances, is dawning. Emerging evidence indicates that …

Introduction Depression is a common disabling psychiatric disorder, which–in extreme
cases–may lead to suicide if untreated or inadequately treated. Despite the availability of …

Alcohol use disorder (AUD) is a public health issue that affects millions of people worldwide
leading to physical, mental and socio-economic consequences. While current treatments for …

Research on the health services' response to substance use disorders and respective
comorbidities holds major relevance due to the increasing prevalence of these ailments. We …

Background Psilocybin-assisted psychotherapy (PAP) is a promising treatment option for
depression, with randomized controlled trials (RCTs) providing preliminary support for its …